SKL2001
产品说明书
 |
同义名 : | Wnt Agonist II; SKL2001 |
| CAS号 : | 909089-13-0 | |
| 货号 : | A660516 | |
| 分子式 : | C14H14N4O3 | |
| 纯度 : | 99%+ | |
| 分子量 : | 286.29 | |
| MDL号 : | MFCD14733081 | |
| 存储条件： |
Pure form Sealed in dry, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
2% DMSO+40% PEG 300+2% Tween 80+water 7 mg/mL |
| 生物活性 | |||
|---|---|---|---|
| 描述 | SKL2001 acts as an agonist for the Wnt/β-catenin signaling pathway and exhibits anti-cancer properties. It achieves stabilization of β-catenin within cells by disrupting the interaction between Axin and β-catenin. Additionally, SKL2001 upregulates Axin2 expression, a downstream component of the Wnt/β-catenin pathway, while not affecting NF-κB, p53 reporter activities, or GSK-3β activity. It promotes osteoblast differentiation at concentrations of 20 and 40 μM and inhibits preadipocyte differentiation at 5, 10, and 30 μM, through the activation of the Wnt/β-catenin pathway. At these same concentrations, SKL2001 also maintains the stability of intracellular β-catenin in 3T3-L1 cells[1]. At a concentration of 40 μM, SKL2001 markedly suppresses the proliferation of HCT116 spheroids without inducing cytotoxic effects, and this suppression can be reversed. Additionally, SKL2001 induces cell cycle arrest in HCT116 spheroids. Furthermore, at the same concentration, SKL2001 promotes the formation of round-shaped spheroids and the expression of E-cadherin[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.49mL 0.70mL 0.35mL |
17.46mL 3.49mL 1.75mL |
34.93mL 6.99mL 3.49mL |
| 参考文献 |
|---|